top of page
Alzheimer’s drug from Eli Lilly wins backing of FDA committee
By David Ovalle and Daniel Gilbert
Jun 10, 2024
The company’s experimental drug was shown in a clinical trial to slow cognitive decline by 35 percent in early disease stages.
bottom of page